

# Dermatology CRO Market to Hit USD 8.6 Billion by 2032, Growing at 6.7% CAGR

*Rising Demand for Dermatological Trials and Advancements in Skin Disease Research Drive Growth*

AUSTIN, TX, UNITED STATES, February 28, 2025 /EINPresswire.com/ --

According to Research by SNS Insider, The [Dermatology CRO market](#) size was valued at USD 4.8 billion in 2023 and is projected to reach USD 8.6 billion by 2032, expanding at a CAGR of 6.7% from 2024 to 2032. The rising burden of dermatological conditions such as psoriasis, eczema, acne, and skin cancer, coupled with the need for innovative treatments, is driving the demand for dermatology CRO services.



## Market Drivers

The increasing number of skin diseases worldwide is the key driver for dermatology CRO market. Skin diseases are among the most prevalent ailments affecting human health, nearly 900 million people globally, according to the World Health Organization (WHO). The growing focus on skin health and an increasing demand for tailor-made and skin-targeted therapies have resulted in an upsurge of dermatological clinical trials. Furthermore, the increasing prevalence of skin cancer and technological advancements, such as biotechnology, which enable the development of novel dermatological treatments, including various biologics and gene therapies, are also driving the market growth. Market growth is also driven by government initiatives and funding for dermatological research. For example, in 2023, the U.S. National Institutes of Health (NIH) committed USD 450 million for dermatology-related research, specifically for diseases including melanoma and autoimmune skin diseases. The European Union's Horizon Europe program, in particular, set out funding for innovative dermatology research projects that are designed to encourage partnerships between CROs and pharmaceutical companies.

Get a Free Sample Report@ <https://www.snsinsider.com/sample-request/5840>

Key Players in Dermatology CRO Market

- Galderma (Cetaphil, Differin)
- ICON PLC (Clinical Trial Management, Data Management Services)
- Parexel (Clinical Trial Management, Regulatory Consulting)
- Crown Bioscience International (PDX Models, In Vitro Assays)
- Sun Pharma (Ilumya, Odomzo)
- Covance (Clinical Development Services, Laboratory Testing)
- Quintiles IMS (Clinical Trial Services, Data Analytics)
- PPD (Pharmaceutical Product Development) (Clinical Trial Management, Laboratory Services)
- Charles River Laboratories (Preclinical Testing, Safety Assessment)
- Medpace (Clinical Trial Management, Regulatory Consulting)
- Syneos Health (Clinical Development Services, Commercialization)
- PRA Health Sciences (Clinical Trial Management, Data Solutions)
- WuXi AppTec (Laboratory Testing, Clinical Development)
- Eurofins Scientific (Bioanalytical Services, Clinical Diagnostics)
- Labcorp Drug Development (Clinical Trial Management, Central Laboratory Services)
- KCR (Clinical Development Solutions, Regulatory Affairs)
- Novotech (Clinical Trial Services, Regulatory Consulting)
- Tigermed (Clinical Trial Management, Data Management)
- Pharmaron (Preclinical Research, Clinical Development)
- ICON Central Laboratories (Central Laboratory Services, Biomarker Analysis)

## Market Segmentation

### By Type

The clinical segment dominated the dermatology CRO market and held a revenue share 75% in 2023. Phase I, Phase II, Phase III, and Phase IV clinical trials are in this segment. Phase III trials accounted for the majority share, because of the high cost related with large patient recruitment and monitoring over time. The Significance of Dermatology CROs are essential for efficient management of these trials, guaranteeing regulatory adherence, and offering specialized knowledge for patient stratification and data analysis. The increasing complexity of dermatological trials, particularly for biologics and immunotherapies, has further boosted the demand for clinical-type services.

### By Service Type

In 2023, the clinical monitoring segment led the market and accounted for 22% of revenue. Clinical monitoring is the process of overseeing clinical trials, ensuring compliance with protocols, and ensuring the integrity of data. This service is essential for dermatology trials which require detailed reporting of skin-related outcomes and adverse events. These services are being increasingly adopted by dermatology CROs, especially with the increasing advent of decentralized clinical trials (DCTs) and virtual monitoring tools which have already had a large impact on the magnitude of efficiencies we can bring to clinical monitoring services.

Need any customization research on Dermatology CRO Market, Enquire Now@

## Regional Analysis

North America dominated the dermatology CRO market in 2023, with 43% of the global revenue. The large share of the region is attributed to the presence of a well-established healthcare infrastructure, high R&D spending, and the presence of top pharmaceutical and biotechnology companies. The U.S. plays a key role thanks to the rising number of skin diseases and strong government funding for dermatology research. According to the American Academy of Dermatology, skin cancer affects one in five Americans, creating a significant demand for dermatology CRO services. Moreover, supportive regulatory environment and leading market players including IQVIA, Parexel, and PPD contribute to the growth of the market in the region.

The dermatology CRO market in the Asia-Pacific region is expected to grow at the fastest rate during the forecast period. The market is driven by rapid improvements in healthcare infrastructure, an increase in healthcare expenditure, and a rise in the prevalence of skin diseases. Governments are investing heavily in dermatology research which means countries like China, India, and Japan are well-positioned to drive innovation in the field supported by government initiatives and partnerships with global CROs. For example, India's National Health Mission (NHM), has started programs to treat rural skin diseases, which creates opportunities for dermatology contract research organizations (CROs). Additionally, the region's large patient pool and cost-effective clinical trial solutions are attracting global pharmaceutical companies, further boosting market growth.

## Recent Developments

- In 2023, IQVIA launched a dedicated dermatology CRO division to provide end-to-end services for dermatology clinical trials, including patient recruitment and real-world evidence generation.
- In January 2024, Parexel introduced an AI-powered platform for dermatology trials, enabling real-time monitoring of skin-related outcomes and enhancing trial efficiency.

Buy Full Research Report on Dermatology CRO Market 2024-2032 @

<https://www.snsinsider.com/checkout/5840>

## About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave

SNS Insider Pvt. Ltd

+1 315 636 4242

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/790003555>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.